(e,e,e,e)-squalene

(e,e,e,e)-squalene is a lipid of Fatty Acyls (FA) class. (e,e,e,e)-squalene is associated with abnormalities such as Hypercholesterolemia and Cataract. The involved functions are known as Process, metaplastic cell transformation, Protein Overexpression, Anabolism and Biosynthetic Pathways. (e,e,e,e)-squalene often locates in Membrane, Protoplasm, Plasma membrane, Tissue membrane and Back. The associated genes with (e,e,e,e)-squalene are Genome, IMPACT gene, GAPDH gene, GTF2I gene and Chromatin. The related lipids are Membrane Lipids, cycloartenol, Sterols, Fatty Acids and Nonesterified Fatty Acids.

Cross Reference

Introduction

To understand associated biological information of (e,e,e,e)-squalene, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with (e,e,e,e)-squalene?

(e,e,e,e)-squalene is suspected in Hypercholesterolemia, Cataract and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with (e,e,e,e)-squalene

MeSH term MeSH ID Detail
Colonic Neoplasms D003110 161 associated lipids
Adenocarcinoma D000230 166 associated lipids
Lung Neoplasms D008175 171 associated lipids
Body Weight D001835 333 associated lipids
Per page 10 20 50 100 | Total 84

PubChem Associated disorders and diseases

What pathways are associated with (e,e,e,e)-squalene

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with (e,e,e,e)-squalene?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with (e,e,e,e)-squalene?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with (e,e,e,e)-squalene?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with (e,e,e,e)-squalene?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with (e,e,e,e)-squalene?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with (e,e,e,e)-squalene

Download all related citations
Per page 10 20 50 100 | Total 1766
Authors Title Published Journal PubMed Link
Michael-Jubeli R et al. High-temperature gas chromatography-mass spectrometry for skin surface lipids profiling. 2011 J. Lipid Res. pmid:20952798
Lama-Muñoz A et al. New hydrothermal treatment of alperujo enhances the content of bioactive minor components in crude pomace olive oil. 2011 J. Agric. Food Chem. pmid:21265536
Cen-Pacheco F et al. Cytotoxic oxasqualenoids from the red alga Laurencia viridis. 2011 Eur J Med Chem pmid:21616566
Raouane M et al. Synthesis, characterization, and in vivo delivery of siRNA-squalene nanoparticles targeting fusion oncogene in papillary thyroid carcinoma. 2011 J. Med. Chem. pmid:21561161
Nowosielski M and Hoffmann M Do the substituent effects affect conformational freedom of squalene in hopene biosynthesis? 2011 J Mol Model pmid:21562825
Hernández-García I et al. [Adverse events after administration of A/H1N1 vaccine to patients]. 2011 Med Clin (Barc) pmid:20199781
Fox CB et al. Effects of emulsifier concentration, composition, and order of addition in squalene-phosphatidylcholine oil-in-water emulsions. 2011 Pharm Dev Technol pmid:20550484
Celia C et al. Gemcitabine-loaded innovative nanocarriers vs GEMZAR: biodistribution, pharmacokinetic features and in vivo antitumor activity. 2011 Expert Opin Drug Deliv pmid:22077480
Tsai TF MF59 adjuvanted seasonal and pandemic influenza vaccines. 2011 Yakugaku Zasshi pmid:22129867
Puig-Barberà J et al. MF59™-adjuvanted seasonal influenza vaccine in young children. 2011 Expert Rev Vaccines pmid:22043952
Viganò A et al. Long-term immunogenicity after one and two doses of a monovalent MF59-adjuvanted A/H1N1 Influenza virus vaccine coadministered with the seasonal 2009-2010 nonadjuvanted Influenza virus vaccine in HIV-infected children, adolescents, and young adults in a randomized controlled trial. 2011 Clin. Vaccine Immunol. pmid:21795458
Huijskens E et al. Immunogenicity, boostability, and sustainability of the immune response after vaccination against Influenza A virus (H1N1) 2009 in a healthy population. 2011 Clin. Vaccine Immunol. pmid:21795459
Pollard AJ and Hill AV Antibody repertoire: embracing diversity. 2011 Sci Transl Med pmid:21795586
Okike IO et al. The immunogenicity of a novel A (H1N1) vaccine in HIV-infected children. 2011 Vaccine pmid:21742005
Kowert BA and Watson MB Diffusion of organic solutes in squalane. 2011 J Phys Chem B pmid:21780767
Andrews N et al. Age-specific effectiveness of an oil-in-water adjuvanted pandemic (H1N1) 2009 vaccine against confirmed infection in high risk groups in England. 2011 J. Infect. Dis. pmid:21148494
Kajaste-Rudnitski A et al. Induction of protective antibody response by MF59-adjuvanted 2009 pandemic A/H1N1v influenza vaccine in HIV-1-infected individuals. 2011 AIDS pmid:21150561
Launay O et al. Safety and immunogenicity of a monovalent 2009 influenza A/H1N1v vaccine adjuvanted with AS03A or unadjuvanted in HIV-infected adults: a randomized, controlled trial. 2011 J. Infect. Dis. pmid:21628666
Piccialli V et al. Isolation of a bis-iodurated tetra-THF as a trace product from the oxidation of squalene with RuOâ‚„ and its double ring expansion to a novel bis-THF-bis-THP compound. 2011 Molecules pmid:21709619
Iannazzo S Pharmacoeconomic evaluation of the MF59--adjuvanted influenza vaccine in the elderly population in Italy. 2011 J Prev Med Hyg pmid:21710816
Seubert A et al. Adjuvanticity of the oil-in-water emulsion MF59 is independent of Nlrp3 inflammasome but requires the adaptor protein MyD88. 2011 Proc. Natl. Acad. Sci. U.S.A. pmid:21690334
Khurana S et al. MF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccines. 2011 Sci Transl Med pmid:21632986
Zhang LW et al. Oil components modulate the skin delivery of 5-aminolevulinic acid and its ester prodrug from oil-in-water and water-in-oil nanoemulsions. 2011 Int J Nanomedicine pmid:21556344
Esposito S et al. Immunogenicity, safety and tolerability of monovalent 2009 pandemic influenza A/H1N1 MF59-adjuvanted vaccine in children and adolescents with Williams or Cornelia De Lange syndrome. 2011 Hum Vaccin pmid:21508673
Ačimovič J et al. Circadian rhythm of cholesterol synthesis in mouse liver: a statistical analysis of the post-squalene metabolites in wild-type and Crem-knock-out mice. 2011 Biochem. Biophys. Res. Commun. pmid:21531203
Siedenburg G and Jendrossek D Squalene-hopene cyclases. 2011 Appl. Environ. Microbiol. pmid:21531832
Tsai TF et al. Explorations of clinical trials and pharmacovigilance databases of MF59®-adjuvanted influenza vaccines for associated cases of narcolepsy. 2011 Scand. J. Infect. Dis. pmid:21534891
Esposito S et al. Influenza A/H1N1 MF59-adjuvanted vaccine in preterm and term children aged 6 to 23 months. 2011 Pediatrics pmid:21464195
Esposito S et al. An open-label, randomized clinical trial assessing immunogenicity, safety and tolerability of pandemic influenza A/H1N1 MF59-adjuvanted vaccine administered sequentially or simultaneously with seasonal virosomal-adjuvanted influenza vaccine to paediatric kidney transplant recipients. 2011 Nephrol. Dial. Transplant. pmid:20974645
Durando P et al. Adjuvants and alternative routes of administration towards the development of the ideal influenza vaccine. 2011 Jan-Feb Hum Vaccin pmid:21245655
Schellenberger MT et al. Evaluation of adjuvants for a candidate conjugate vaccine against benzo[a]pyrene. 2011 Jan-Feb Hum Vaccin pmid:21245662
Dorea JG Safety of thimerosal in vaccines: for whom and how many doses? 2011 Mar-Apr Therapie pmid:23189333
Kozlov VG and Viktorova EG [Evaluation of the efficiency and reactogenicity of emulsion-based adjuvant systems in the manufacture of polyclonal enteroviral diagnostic sera]. 2011 Mar-Apr Vopr. Virusol. pmid:21545042
Della Cioppa G et al. Superior immunogenicity of seasonal influenza vaccines containing full dose of MF59 (®) adjuvant: results from a dose-finding clinical trial in older adults. 2012 Hum Vaccin Immunother pmid:22426371
Ikematsu H et al. Evaluation of immune response following one dose of an AS03A-adjuvanted H1N1 2009 pandemic influenza vaccine in Japanese adults 65 years of age or older. 2012 Hum Vaccin Immunother pmid:22854661
Nakazawa A et al. Optimization of culture conditions of the thraustochytrid Aurantiochytrium sp. strain 18W-13a for squalene production. 2012 Bioresour. Technol. pmid:22023965
Niehaus TD et al. Functional identification of triterpene methyltransferases from Botryococcus braunii race B. 2012 J. Biol. Chem. pmid:22241476
Iorio AM et al. Influenza viruses and cross-reactivity in healthy adults: humoral and cellular immunity induced by seasonal 2007/2008 influenza vaccination against vaccine antigens and 2009 A(H1N1) pandemic influenza virus. 2012 Vaccine pmid:22245606
Sémiramoth N et al. Self-assembled squalenoylated penicillin bioconjugates: an original approach for the treatment of intracellular infections. 2012 ACS Nano pmid:22482704
Langley JM et al. Safety and immunogenicity of 2010-2011 H1N12009-containing trivalent inactivated influenza vaccine in children 12-59 months of age previously given AS03-adjuvanted H1N12009 pandemic vaccine: a PHAC/CIHR Influenza Research Network (PCIRN) study. 2012 Vaccine pmid:22469860
Fukase H et al. Assessment of the immunogenicity and safety of varying doses of an MF59®-adjuvanted cell culture-derived A/H1N1 pandemic influenza vaccine in Japanese paediatric, adult and elderly subjects. 2012 Vaccine pmid:22472791
Suthiwong J et al. A new phenolic compound from the stem of Hymenocardia wallichii. 2012 J Asian Nat Prod Res pmid:22423644
Zhang XH et al. Chemical composition of volatile oils from the pericarps of Indian sandalwood (Santalum album) by different extraction methods. 2012 Nat Prod Commun pmid:22428257
Guzmán Herrador BR et al. Usefulness of health registries when estimating vaccine effectiveness during the influenza A(H1N1)pdm09 pandemic in Norway. 2012 BMC Infect. Dis. pmid:22429643
Hatz C et al. A randomized clinical trial to identify the optimal antigen and MF59(®) adjuvant dose of a monovalent A/H1N1 pandemic influenza vaccine in healthy adult and elderly subjects. 2012 Vaccine pmid:22446638
Desmaële D et al. Squalenoylation: a generic platform for nanoparticular drug delivery. 2012 J Control Release pmid:21840355
Naziri E et al. Recovery of squalene from wine lees using ultrasound assisted extraction-a feasibility study. 2012 J. Agric. Food Chem. pmid:22888984
Czajka H et al. A phase II, randomised clinical trial to demonstrate the non-inferiority of low-dose MF59-adjuvanted pre-pandemic A/H5N1 influenza vaccine in adult and elderly subjects. 2012 J Prev Med Hyg pmid:23362618
Takami T et al. A genetic and pharmacological analysis of isoprenoid pathway by LC-MS/MS in fission yeast. 2012 PLoS ONE pmid:23145048
Langley JM et al. A randomized, controlled non-inferiority trial comparing A(H1N1)pmd09 vaccine antigen, with and without AS03 adjuvant system, co-administered or sequentially administered with an inactivated trivalent seasonal influenza vaccine. 2012 BMC Infect. Dis. pmid:23110320